Aiforia Technologies (AIFORIA) Q4 2025 earnings summary

Executive summary

• Clinical sector revenue grew 68% in FY 2025, driven by portfolio expansion, commercial execution, and flagship customer wins.

• Group revenue increased 24% year-over-year to EUR 3,535 thousand.

• Strategic partnerships, including Siemens Healthineers and Orion, supported growth.

• Achieved IVDR certification for five new AI solutions, expanding the CE-IVD marked product portfolio to eleven.

• Actions taken to improve cost structure and efficiency, with secured funding and leadership changes.

Financial highlights

• Group revenue rose 24% to EUR 3,535 thousand compared to the previous year.

• Clinical sector revenue increased 68% year-over-year.

• EBITDA improved to EUR -6,045 thousand from EUR -8,220 thousand.

• EBIT improved to EUR -11,183 thousand from EUR -12,195 thousand.

• Cash and cash equivalents at year-end were EUR 9,529 thousand.

Outlook and guidance

• No formal short-term outlook; medium-term targets include financial independence by 2027 and covering 80% of the pathologist's workflow by 2030.

• Aim to reach 50 key clinical accounts and leverage technology beyond diagnostic support by 2030.

• Continued investment in technology and market capture, with flexibility to pursue profitability or additional funding.